Improving tuberculosis treatment through community pharmacies in Uganda.
Official title: Integrating tuberculosis treatment into community pharmacies to improve TB/HIV outcomes in Uganda.
Funded at Infectious Diseases Institute · NIH-10995251 · Data updated 2026-11-12
This study is looking to improve how people with HIV in Uganda get treated for tuberculosis by making TB medications more accessible through local pharmacies, so they can receive better care and have a higher chance of recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Infectious Diseases Institute NIH-funded |
| Lab location | 1 site (Kampala, Uganda) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $109,704 |
| NIH project number | 1K43TW012839-01 |
| Project ID | NIH-10995251 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are also diagnosed with tuberculosis.
✕Less likely to help
Patients who do not have HIV or tuberculosis may not receive any benefit from this research.
What this research studies
This research aims to enhance tuberculosis (TB) treatment outcomes for individuals living with HIV in Uganda by integrating TB treatment services into community pharmacies. The approach focuses on addressing barriers to effective prevention, diagnosis, and treatment through person-centered strategies that are relevant to the local context. By leveraging community pharmacies, the project seeks to improve access to medications, enhance adherence to treatment, and ultimately increase the success rates of TB treatment among this vulnerable population.
Why it matters
Potential benefit: If successful, this research could significantly improve TB treatment outcomes for people living with HIV in Uganda.
How similar studies have gone: Previous research has shown success in using community pharmacies to improve access to antiretroviral therapy, suggesting a promising approach for TB treatment as well.
Where this research is happening
-
Infectious Diseases Institute
Kampala, Uganda Active
Researchers
- Principal investigator: Izudi, Jonathan — Infectious Diseases Institute
- Study coordinator: Izudi, Jonathan
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.